A recent case report and literature review investigates a potential link between mRNA COVID-19 vaccination and hematopoietic malignancy. The study details a 38-year-old woman who developed B-lymphoblastic leukemia/lymphoma shortly after her second mRNA vaccine dose. Symptoms, including pain and fever, progressed over months, leading to a bone marrow biopsy revealing a precursor B-lymphoid neoplasm. The patient achieved remission after chemotherapy but later experienced a central nervous system relapse.
The review analyzed 30 studies, with 28 focusing on hemato-lymphoproliferative disorders post-vaccination, including B-cell, T-cell, and myeloid malignancies. Authors emphasize these are observations requiring further investigation, not definitive proof of causation, noting a lack of specific molecular studies.
Proposed mechanisms under examination include altered immune signaling, reduced interferon responses, and increased TGF-Beta activity. Potential accumulation of lipid nanoparticle formulations in bone marrow is also discussed as a theoretical contributor to impaired immune surveillance. Researchers call for population-based studies and molecular assessments to determine any true carcinogenic risk.